TELAVANCIN HYDROCHLORIDE - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for telavancin hydrochloride and what is the scope of patent protection?

Telavancin hydrochloride is the generic ingredient in one branded drug marketed by Cumberland and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Telavancin hydrochloride has thirty-three patent family members in eighteen countries.

One supplier is listed for this compound.

Summary for TELAVANCIN HYDROCHLORIDE

International Patents:	33
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	15
Clinical Trials:	16
Patent Applications:	21
What excipients (inactive ingredients) are in TELAVANCIN HYDROCHLORIDE?	TELAVANCIN HYDROCHLORIDE excipients list
DailyMed Link:	TELAVANCIN HYDROCHLORIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TELAVANCIN HYDROCHLORIDE

Generic Entry Date for TELAVANCIN HYDROCHLORIDE^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up Dosage: POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TELAVANCIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aaron Cook	Phase 4
Joseph L. Kuti, PharmD	Phase 4
Cumberland Pharmaceuticals, Inc.	Phase 4

See all TELAVANCIN HYDROCHLORIDE clinical trials

Pharmacology for TELAVANCIN HYDROCHLORIDE

Drug Class	Lipoglycopeptide Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for TELAVANCIN HYDROCHLORIDE

J01XA	Glycopeptide antibacterials
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for TELAVANCIN HYDROCHLORIDE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for TELAVANCIN HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009	⤷ Sign Up	⤷ Sign Up
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009	⤷ Sign Up	⤷ Sign Up
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009	⤷ Sign Up	⤷ Sign Up
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009	⤷ Sign Up	⤷ Sign Up
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009	⤷ Sign Up	⤷ Sign Up
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009	⤷ Sign Up	⤷ Sign Up
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for TELAVANCIN HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Cyprus	1113773		⤷ Sign Up
Taiwan	I342312		⤷ Sign Up
South Korea	20120037025	HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE	⤷ Sign Up
South Korea	20060094082	HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE	⤷ Sign Up
South Korea	101166250		⤷ Sign Up
European Patent Office	2495251	CHLORHYDRATES D'UN DERIVE DE GLYCOPEPTIDE PHOSPHONATE (HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE)	⤷ Sign Up
Mexico	PA06004336	SALES DE CLORHIDRATO DE UN DERIVADO GLICOPEPTIDO FOSFONATO. (HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE.)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for TELAVANCIN HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1292612	2011C/045	Belgium	⤷ Sign Up	PRODUCT NAME: VIBATIV - TELAVANCINE; AUTHORISATION NUMBER AND DATE: EU/1/11/705-001 20110902
1292612	1190036-2	Sweden	⤷ Sign Up	PRODUCT NAME: TELAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV INNEFATTANDE TELAVANCINHYDROKLORID; REG. NO/DATE: EU/1/11/705/001 20110902
1292612	132012902025885	Italy	⤷ Sign Up	PRODUCT NAME: TELAVANCINA(VIBATIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/705/001-002, 20110902
1292612	36/2011	Austria	⤷ Sign Up	PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
1292612	PA2012002,C1292612	Lithuania	⤷ Sign Up	PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
1292612	CA 2011 00033	Denmark	⤷ Sign Up	PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID
1292612	C 2012 002	Romania	⤷ Sign Up	PRODUCT NAME: TELAVANCIN SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIAINCLUZAND CLORHIDRAT DE TELAVANCIN; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/705/001, RO EU/1/11/705/002; DATE OF NATIONAL AUTHORISATION: 20110902; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/705/001, EU/1/11/705/002; DATE OF FIRST AUTHORISATION IN EEA: 20110902
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.